Loading
Animal Virus Infections Studies / Respiratory Viral Infections Research · Journal article
Journal of Clinical Medicine · August 26, 2026
A consensus or society position rather than new primary data.
This is a clinical guidance document proposing a jurisdiction-adaptable implementation pathway for RSV vaccination in adults with cardiovascular disease, synthesizing evidence that establishes protection against RSV respiratory disease and hospitalization but does not demonstrate reductions in cardiovascular events, myocardial infarction, heart failure hospitalization, or major adverse cardiovascular events. The authors prioritize routine preventive care integration while framing cardiovascular-event reduction as a research priority rather than a demonstrated indication.
Narrative synthesis and implementation framework development. Adults with cardiovascular disease; framework targets those aged ≥75 years and those aged 50–74 years with high-risk cardiovascular conditions.. Intervention: RSV vaccination integrated into cardiovascular care with assessment across cardiology, heart failure, primary care, pharmacy, and long-term care settings..
DAN-RSV reduced all-cause cardiorespiratory hospitalization but did not demonstrate significant reductions in cardiovascular hospitalization, myocardial infarction, heart failure hospitalization, atrial fibrillation, stroke, cardiovascular death, or major adverse cardiovascular events Randomized trials establish protection against RSV-associated lower respiratory tract disease and respiratory illness Real-world studies support effectiveness against RSV-related hospitalization
Source does not report adverse event rates, contraindications, or cost-effectiveness data. DAN-RSV reduced all-cause cardiorespiratory hospitalization but did not demonstrate significant reductions in cardiovascular hospitalization, myocardial infarction, heart failure hospitalization, atrial fibrillation, stroke, cardiovascular death, or major adverse cardiovascular events
Clinicians should integrate RSV vaccination assessment into routine cardiovascular care for eligible adults, grounded in documented respiratory and cardiorespiratory hospitalization benefits. However, the absence of demonstrated cardiovascular-event reduction means vaccination should not currently be positioned as a strategy to prevent myocardial infarction, heart failure, or stroke.
A narratively synthesized review proposing a clinical implementation framework for RSV vaccination in cardiovascular disease, grounded in trial evidence for respiratory but not cardiovascular endpoints.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should integrate RSV vaccination assessment into routine cardiovascular care for eligible adults, grounded in documented respiratory and cardiorespiratory hospitalization benefits. However, the absence of demonstrated cardiovascular-event reduction means vaccination should not currently be positioned as a strategy to prevent myocardial infarction, heart failure, or stroke.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Respiratory syncytial virus (RSV) causes morbidity in older adults with cardiovascular disease, in whom infection may precipitate severe lower respiratory tract disease, hospitalization, functional decline, and cardiovascular destabilization. We evaluate the evidence for RSV vaccination in cardiovascular disease and propose a jurisdiction-adaptable framework for integrating vaccination into cardiovascular care. Methods: Observational studies, randomized trials, pragmatic and test-negative studies, prespecified cardiovascular analyses of DAN-RSV, and eligibility recommendations were narratively synthesized and translated into a pathway encompassing patient identification, eligibility and risk assessment, vaccine delivery and co-administration, documentation, and follow-up. Results: Acute cardiac events are frequent during RSV hospitalization, and cardiovascular risk may persist after infection. Randomized trials establish protection against RSV-associated lower respiratory tract disease and respiratory illness, while real-world studies support effectiveness against RSV-related hospitalization. DAN-RSV reduced all-cause cardiorespiratory hospitalization but did not demonstrate significant reductions in cardiovascular hospitalization, myocardial infarction, heart failure (HF) hospitalization, atrial fibrillation, stroke, cardiovascular death, or major adverse cardiovascular events; observational associations with lower post-vaccination cardiovascular-event rates remain hypothesis-generating. The framework prioritizes adults aged ≥75 years and those aged 50–74 years with high-risk cardiovascular conditions where consistent with national recommendations, embeds vaccination assessment across cardiology, HF, primary care, pharmacy, and long-term care, and incorporates co-administration, documentation, and outcome surveillance. Conclusions: The principal contribution is a pathway for moving RSV vaccination from recommendation to routine preventive care for adults with cardiovascular disease. It anchors implementation in established RSV and cardiorespiratory benefits while treating cardiovascular-event reduction as a research priority rather than a demonstrated indication.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.